Topical Tacrolimus, Clobetasol, and Minoxidil for Primary Cicatricial Alopecias: A Retrospective Analysis of Clinical Outcomes and Safety

    August 2025 in “ Skin Appendage Disorders ”
    Anna Brinks, Caitlin A. Kearney, Carli D. Needle, Akshay Pulavarty, Alberto Spindler, D. Maas, Loren D. Krueger, Kristen I. Lo Sicco, Jerry Shapiro
    New to Minoxidil? There is a guide in the encyclopedia. Read the guide →
    Studysummary This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well. Our plain-language summary of this paper — not a Tressless recommendation.
    This retrospective analysis evaluated the safety and efficacy of a topical combination of tacrolimus, clobetasol, and minoxidil (TCM) in 82 patients with primary cicatricial alopecias (PCAs), primarily frontal fibrosing alopecia or lichen planopilaris. The study found that TCM, typically used 1-2 times daily for an average of 24.5 months, was well-tolerated, with 62.2% of patients experiencing no adverse effects. Improvements were noted in provider-assessed inflammation and disease status in 69.5% and 76.9% of patients, respectively, along with enhanced objective hair measurements. The findings suggest that TCM is an effective treatment option for PCAs, either alone or alongside other therapies.
    Discuss this study in the Community →